AI Engines For more Details: Perplexity Kagi Labs You
Diarrhea: Loperamide is most commonly used to treat acute and chronic diarrhea, including traveler's diarrhea and diarrhea associated with inflammatory bowel disease (IBD).
Irritable Bowel Syndrome with Diarrhea (IBS-D): Loperamide may be used to alleviate diarrhea symptoms in individuals with IBS-D, although it does not directly treat the underlying condition.
Gastroenteritis: Loperamide can help reduce the frequency and severity of diarrhea caused by viral or bacterial gastroenteritis.
Colostomy or Ileostomy: Loperamide may be used to regulate bowel movements and reduce diarrhea in individuals with colostomies or ileostomies.
Short Bowel Syndrome: Loperamide may be used to manage diarrhea in individuals with short bowel syndrome, a condition characterized by malabsorption due to surgical removal of a significant portion of the small intestine.
Microscopic Colitis: Loperamide may provide relief from diarrhea symptoms associated with microscopic colitis, a type of inflammatory bowel disease characterized by chronic diarrhea.
Chemotherapy-Induced Diarrhea: Loperamide may be used to manage diarrhea caused by chemotherapy treatments, although its effectiveness in this context may vary.
Radiation-Induced Diarrhea: Loperamide may help alleviate diarrhea associated with radiation therapy to the abdomen or pelvis.
Dumping Syndrome: Loperamide may be used to reduce the frequency of bowel movements and improve symptoms in individuals with dumping syndrome, a condition characterized by rapid gastric emptying and subsequent diarrhea after meals.
Functional Diarrhea: Loperamide may be prescribed to manage chronic functional diarrhea, which is diarrhea without an identifiable organic cause.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Increases |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium animalis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
| species | Bifidobacterium pseudolongum | Increases |
| species | Corynebacterium stationis | Increases |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| species group | Pseudomonas putida group | Increases |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.7 | 0.2 | 2.5 |
| Acne | 1.1 | 1.5 | -0.36 |
| ADHD | 4.6 | 2.8 | 0.64 |
| Age-Related Macular Degeneration and Glaucoma | 1 | 1.4 | -0.4 |
| Allergic Rhinitis (Hay Fever) | 4.2 | 3 | 0.4 |
| Allergies | 5.4 | 5 | 0.08 |
| Allergy to milk products | 3.7 | 1.2 | 2.08 |
| Alopecia (Hair Loss) | 2.6 | 0.9 | 1.89 |
| Alzheimer's disease | 7.3 | 11.1 | -0.52 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 5.2 | 1.1 | 3.73 |
| Ankylosing spondylitis | 4.9 | 2.2 | 1.23 |
| Anorexia Nervosa | 2.2 | 5 | -1.27 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.1 | 13 |
| Asthma | 3.9 | 4.4 | -0.13 |
| Atherosclerosis | 2 | 2.3 | -0.15 |
| Atrial fibrillation | 4.8 | 4.1 | 0.17 |
| Autism | 10.6 | 10.5 | 0.01 |
| Autoimmune Disease | 0.5 | 1.5 | -2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 2.2 | -2.2 | |
| Biofilm | 1.6 | 0.8 | 1 |
| Bipolar Disorder | 3 | 3.1 | -0.03 |
| Brain Trauma | 2 | 1.8 | 0.11 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.5 | 1.2 | -1.4 |
| Carcinoma | 4 | 3.1 | 0.29 |
| Celiac Disease | 3.7 | 5.5 | -0.49 |
| Cerebral Palsy | 1.5 | 2.6 | -0.73 |
| Chronic Fatigue Syndrome | 4.5 | 7.8 | -0.73 |
| Chronic Kidney Disease | 3.9 | 4.2 | -0.08 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3.9 | 4.7 | -0.21 |
| Chronic Urticaria (Hives) | 0.6 | 2 | -2.33 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 3.1 | -3.43 |
| Cognitive Function | 4.2 | 1.8 | 1.33 |
| Colorectal Cancer | 8.1 | 4.6 | 0.76 |
| Constipation | 2.4 | 2.1 | 0.14 |
| Coronary artery disease | 2.4 | 5.8 | -1.42 |
| COVID-19 | 8.4 | 15.1 | -0.8 |
| Crohn's Disease | 11.6 | 10.4 | 0.12 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.2 | 3.1 | -14.5 |
| deep vein thrombosis | 2.9 | 2.7 | 0.07 |
| Denture Wearers Oral Shifts | 1 | 0.6 | 0.67 |
| Depression | 13.9 | 12.7 | 0.09 |
| Dermatomyositis | 0.8 | 0.2 | 3 |
| Eczema | 1.8 | 1.3 | 0.38 |
| Endometriosis | 3.3 | 3.3 | 0 |
| Eosinophilic Esophagitis | 1.5 | -1.5 | |
| Epilepsy | 4.1 | 3.5 | 0.17 |
| erectile dysfunction | 2.7 | 0.5 | 4.4 |
| Fibromyalgia | 3.8 | 2.4 | 0.58 |
| Functional constipation / chronic idiopathic constipation | 6.2 | 5.7 | 0.09 |
| gallstone disease (gsd) | 4.5 | 1.1 | 3.09 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 1.3 | 0.38 |
| Generalized anxiety disorder | 3.6 | 2.9 | 0.24 |
| Glioblastoma | 2.2 | -2.2 | |
| Gout | 1.4 | 1.2 | 0.17 |
| Graves' disease | 2 | 4.5 | -1.25 |
| Gulf War Syndrome | 1.5 | 2 | -0.33 |
| Halitosis | 1.8 | 0.9 | 1 |
| Hashimoto's thyroiditis | 5.3 | 2.2 | 1.41 |
| Heart Failure | 4.5 | 3.9 | 0.15 |
| hemorrhagic stroke | 1.7 | 0.3 | 4.67 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.8 | 2.1 | -1.63 |
| High Histamine/low DAO | 0.7 | 1.1 | -0.57 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.7 | -1.33 |
| hyperglycemia | 2.2 | 2.6 | -0.18 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 1.5 | -0.67 |
| hypersomnia | 0.1 | 1.5 | -14 |
| hypertension (High Blood Pressure | 6.9 | 8.2 | -0.19 |
| Hypothyroidism | 1.1 | 4.1 | -2.73 |
| Hypoxia | 1.9 | 1.1 | 0.73 |
| IgA nephropathy (IgAN) | 2 | 5.2 | -1.6 |
| Inflammatory Bowel Disease | 7.5 | 9.5 | -0.27 |
| Insomnia | 4.1 | 4.9 | -0.2 |
| Intelligence | 2.8 | 1.8 | 0.56 |
| Intracranial aneurysms | 3.1 | 1.4 | 1.21 |
| Irritable Bowel Syndrome | 9.7 | 7.8 | 0.24 |
| ischemic stroke | 2.7 | 3.5 | -0.3 |
| Liver Cirrhosis | 7.8 | 5.1 | 0.53 |
| Long COVID | 10.7 | 10.1 | 0.06 |
| Low bone mineral density | 0.5 | 2.4 | -3.8 |
| Lung Cancer | 0.7 | 2.6 | -2.71 |
| Mast Cell Issues / mastitis | 0.4 | 1.4 | -2.5 |
| ME/CFS with IBS | 0.4 | 1.5 | -2.75 |
| ME/CFS without IBS | 1.2 | 2.7 | -1.25 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.7 | 1.3 | -0.86 |
| Metabolic Syndrome | 8.8 | 11 | -0.25 |
| Mood Disorders | 12.9 | 10.6 | 0.22 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.4 | 1 |
| Multiple Sclerosis | 4.8 | 8.4 | -0.75 |
| Multiple system atrophy (MSA) | 1.6 | 0.7 | 1.29 |
| myasthenia gravis | 1.6 | 1.1 | 0.45 |
| neuropathic pain | 3.4 | -3.4 | |
| Neuropathy (all types) | 2.2 | 2.1 | 0.05 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 1 | -0.11 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.6 | 6 | -0.07 |
| NonCeliac Gluten Sensitivity | 1.8 | 1 | 0.8 |
| Obesity | 12.1 | 11.4 | 0.06 |
| obsessive-compulsive disorder | 6.4 | 5.4 | 0.19 |
| Osteoarthritis | 3.3 | 2.1 | 0.57 |
| Osteoporosis | 2.8 | 2.8 | 0 |
| pancreatic cancer | 0.8 | 0.8 | 0 |
| Parkinson's Disease | 7.6 | 10.5 | -0.38 |
| Peanut Allergy | 0.5 | -0.5 | |
| Polycystic ovary syndrome | 7.8 | 4.3 | 0.81 |
| Postural orthostatic tachycardia syndrome | 0.4 | 0.3 | 0.33 |
| Premenstrual dysphoric disorder | 1 | 0.9 | 0.11 |
| primary biliary cholangitis | 1.5 | 2.8 | -0.87 |
| Primary sclerosing cholangitis | 2.1 | 4.5 | -1.14 |
| Psoriasis | 3.1 | 4.1 | -0.32 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.9 | 6.7 | 0.33 |
| Rosacea | 1.4 | 0.7 | 1 |
| Schizophrenia | 6.3 | 5.8 | 0.09 |
| scoliosis | 1.3 | 0.9 | 0.44 |
| sensorineural hearing loss | 0.5 | -0.5 | |
| Sjögren syndrome | 2.8 | 3.8 | -0.36 |
| Sleep Apnea | 3 | 2.9 | 0.03 |
| Slow gastric motility / Gastroparesis | 1 | 1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.1 | 2.1 | |
| Stress / posttraumatic stress disorder | 2.3 | 4.1 | -0.78 |
| Systemic Lupus Erythematosus | 4.5 | 3.8 | 0.18 |
| Tic Disorder | 2.4 | 1.4 | 0.71 |
| Tourette syndrome | 0.8 | 0.8 | 0 |
| Type 1 Diabetes | 5.8 | 3.4 | 0.71 |
| Type 2 Diabetes | 10.1 | 9.6 | 0.05 |
| Ulcerative colitis | 9.3 | 9.2 | 0.01 |
| Unhealthy Ageing | 4.2 | 3.3 | 0.27 |
| Vitiligo | 2.8 | 1.6 | 0.75 |
